Figure 3. Forest Plot of Analyses of Individual Components of the Primary and Key Secondary Outcomes (ITT Population, REDUCE-IT).

Figure 3Forest Plot of Analyses of Individual Components of the Primary and Key Secondary Outcomes (ITT Population, REDUCE-IT)

AMR101 = icosapent ethyl; CI = confidence interval; ITT = intention-to-treat.

Source: Clinical Study Report for REDUCE-IT1.

From: Appendix 3, Detailed Outcome Data

Cover of Clinical Review Report: Icosapent Ethyl (Vascepa)
Clinical Review Report: Icosapent Ethyl (Vascepa): (HLS Therapeutics Inc.): Indication: Prevention of cardiovascular events in statin-treated patients [Internet].
Copyright © 2020 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.